BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose Mapping After Endoradiotherapy with 177 Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days. J Nucl Med 2018;59:75-81. [DOI: 10.2967/jnumed.117.193706] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging 2019;46:2536-44. [PMID: 31440799 DOI: 10.1007/s00259-019-04485-3] [Cited by in Crossref: 91] [Cited by in F6Publishing: 67] [Article Influence: 30.3] [Reference Citation Analysis]
2 Sgouros G, Frey E, Du Y, Hobbs R, Bolch W. Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box. Eur J Nucl Med Mol Imaging 2021. [PMID: 34782911 DOI: 10.1007/s00259-021-05583-x] [Reference Citation Analysis]
3 Abbott EM, Falzone N, Lenzo N, Vallis KA. Combining External Beam Radiation and Radionuclide Therapies: Rationale, Radiobiology, Results and Roadblocks. Clin Oncol (R Coll Radiol) 2021;33:735-43. [PMID: 34544640 DOI: 10.1016/j.clon.2021.09.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Turner JH. An introduction to the clinical practice of theranostics in oncology. Br J Radiol 2018;91:20180440. [PMID: 30179054 DOI: 10.1259/bjr.20180440] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
5 Huizing DMV, de Wit-van der Veen BJ, Verheij M, Stokkel MPM. Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. EJNMMI Res 2018;8:89. [PMID: 30159614 DOI: 10.1186/s13550-018-0443-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
6 Mok GSP, Dewaraja YK. Recent advances in voxel-based targeted radionuclide therapy dosimetry. Quant Imaging Med Surg 2021;11:483-9. [PMID: 33532249 DOI: 10.21037/qims-20-1006] [Reference Citation Analysis]
7 Krasikova RN. Potential of PET in Tumor Theranostics. Radiochemistry 2019;61:645-55. [DOI: 10.1134/s1066362219060018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Kosmala A, Serfling SE, Dreher N, Lindner T, Schirbel A, Lapa C, Higuchi T, Buck AK, Weich A, Werner RA. Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography. Cancers (Basel) 2022;14:2609. [PMID: 35681588 DOI: 10.3390/cancers14112609] [Reference Citation Analysis]
9 Pandit-Taskar N, Iravani A, Lee D, Jacene H, Pryma D, Hope T, Saboury B, Capala J, Wahl RL. Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. J Nucl Med 2021;62:60S-72S. [PMID: 34857623 DOI: 10.2967/jnumed.121.262977] [Reference Citation Analysis]
10 Mora-Ramirez E, Santoro L, Cassol E, Ocampo-Ramos JC, Clayton N, Kayal G, Chouaf S, Trauchessec D, Pouget JP, Kotzki PO, Deshayes E, Bardiès M. Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy. Med Phys 2020;47:4602-15. [PMID: 32632928 DOI: 10.1002/mp.14375] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
11 Qi Y, Liu X, Li J, Yao H, Yuan S. Fluorine-18 labeled amino acids for tumor PET/CT imaging. Oncotarget 2017;8:60581-8. [PMID: 28947996 DOI: 10.18632/oncotarget.19943] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
12 Xu L, Meng Q, Yao X, Yang R, Zhang P, Li R, Wang F. Dosimetry of 177Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China. Appl Radiat Isot 2022;179:109975. [PMID: 34741954 DOI: 10.1016/j.apradiso.2021.109975] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hänscheid H, Lassmann M. Will SPECT/CT Cameras Soon Be Able to Display Absorbed Doses? Dosimetry from Single-Activity-Concentration Measurements. J Nucl Med 2020;61:1028-9. [DOI: 10.2967/jnumed.119.239970] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
14 Peters SMB, Privé BM, de Bakker M, de Lange F, Jentzen W, Eek A, Muselaers CHJ, Mehra N, Witjes JA, Gotthardt M, Nagarajah J, Konijnenberg MW. Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. Eur J Nucl Med Mol Imaging 2021. [PMID: 34218300 DOI: 10.1007/s00259-021-05471-4] [Reference Citation Analysis]
15 Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi Kumar A. Radiation Dosimetry in 177Lu-PSMA-617 Therapy. Semin Nucl Med 2021:S0001-2998(21)00090-8. [PMID: 34893320 DOI: 10.1053/j.semnuclmed.2021.11.003] [Reference Citation Analysis]
16 Götz TI, Schmidkonz C, Lang EW, Maier A, Kuwert T, Ritt P. Factors affecting accuracy of S values and determination of time-integrated activity in clinical Lu-177 dosimetry. Ann Nucl Med 2019;33:521-31. [DOI: 10.1007/s12149-019-01365-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Tran-Gia J, Salas-Ramirez M, Lassmann M. What You See Is Not What You Get: On the Accuracy of Voxel-Based Dosimetry in Molecular Radiotherapy. J Nucl Med 2020;61:1178-86. [PMID: 31862802 DOI: 10.2967/jnumed.119.231480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Del Prete M, Arsenault F, Saighi N, Zhao W, Buteau FA, Celler A, Beauregard JM. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT. EJNMMI Phys 2018;5:25. [PMID: 30318563 DOI: 10.1186/s40658-018-0224-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
19 Sandström M, Freedman N, Fröss-Baron K, Kahn T, Sundin A. Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points. EJNMMI Phys 2020;7:73. [PMID: 33296054 DOI: 10.1186/s40658-020-00339-2] [Reference Citation Analysis]
20 Rinscheid A, Lee J, Kletting P, Beer AJ, Glatting G. A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapy. Z Med Phys 2019;29:314-25. [PMID: 30611606 DOI: 10.1016/j.zemedi.2018.12.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Kurth J, Heuschkel M, Tonn A, Schildt A, Hakenberg OW, Krause BJ, Schwarzenböck SM. Streamlined Schemes for Dosimetry of 177Lu-Labeled PSMA Targeting Radioligands in Therapy of Prostate Cancer. Cancers (Basel) 2021;13:3884. [PMID: 34359784 DOI: 10.3390/cancers13153884] [Reference Citation Analysis]
22 Devasia TP, Dewaraja YK, Frey KA, Wong KK, Schipper MJ. A Novel Time-Activity Information-Sharing Approach Using Nonlinear Mixed Models for Patient-Specific Dosimetry with Reduced Imaging Time Points: Application in SPECT/CT After 177Lu-DOTATATE. J Nucl Med 2021;62:1118-25. [PMID: 33443063 DOI: 10.2967/jnumed.120.256255] [Reference Citation Analysis]
23 Chicheportiche A, Sason M, Godefroy J, Krausz Y, Zidan M, Oleinikov K, Meirovitz A, Gross DJ, Grozinsky-Glasberg S, Ben-Haim S. Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study. EJNMMI Phys 2021;8:63. [PMID: 34436698 DOI: 10.1186/s40658-021-00409-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Maurer S, Herhaus P, Lippenmeyer R, Hänscheid H, Kircher M, Schirbel A, Maurer HC, Buck AK, Wester HJ, Einsele H, Grigoleit GU, Keller U, Lapa C. Side Effects of CXC-Chemokine Receptor 4-Directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation. J Nucl Med 2019;60:1399-405. [PMID: 30850502 DOI: 10.2967/jnumed.118.223420] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
25 Graves SA, Bageac A, Crowley JR, Merlino DAM. Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities. J Nucl Med 2021;62:48S-59S. [PMID: 34857622 DOI: 10.2967/jnumed.121.262752] [Reference Citation Analysis]
26 Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry. EJNMMI Phys 2020;7:41. [PMID: 32556844 DOI: 10.1186/s40658-020-00311-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, Konijnenberg M, Cremonesi M, Verburg FA, Bernhardt P, Eberlein U, Gear J. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05727-7] [Reference Citation Analysis]
28 Rosar F, Schön N, Bohnenberger H, Bartholomä M, Stemler T, Maus S, Khreish F, Ezziddin S, Schaefer-Schuler A. Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy. EJNMMI Phys 2021;8:40. [PMID: 33950333 DOI: 10.1186/s40658-021-00385-4] [Reference Citation Analysis]
29 Malcolm JC, Falzone N, Gains JE, Aldridge MD, Mirando D, Lee BQ, Gaze MN, Vallis KA. Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [177Lu]Lu-DOTATATE. EJNMMI Phys 2022;9. [DOI: 10.1186/s40658-022-00436-4] [Reference Citation Analysis]
30 Zhao W, Esquinas PL, Frezza A, Hou X, Beauregard JM, Celler A. Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a 177Lu-DOTATATE patient study. Phys Med Biol 2019;64:175006. [PMID: 31287093 DOI: 10.1088/1361-6560/ab3039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
31 Capala J, Graves SA, Scott A, Sgouros G, James SS, Zanzonico P, Zimmerman BE. Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources. J Nucl Med 2021;62:3S-11S. [PMID: 34857621 DOI: 10.2967/jnumed.121.262749] [Reference Citation Analysis]
32 Sundlöv A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, Hallqvist A, Bernhardt P, Svensson J. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging 2022. [PMID: 35451612 DOI: 10.1007/s00259-022-05786-w] [Reference Citation Analysis]
33 Santoro L, Mora-Ramirez E, Trauchessec D, Chouaf S, Eustache P, Pouget JP, Kotzki PO, Bardiès M, Deshayes E. Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [177Lu-[DOTA0, Tyr3]-octreotate. EJNMMI Res 2018;8:103. [PMID: 30498938 DOI: 10.1186/s13550-018-0459-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
34 Widjaja L, Derlin T, Ross TL, Bengel FM, Werner RA. Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy. Prostate 2022;82:86-96. [PMID: 34633090 DOI: 10.1002/pros.24250] [Reference Citation Analysis]
35 Ligonnet T, Pistone D, Auditore L, Italiano A, Amato E, Campennì A, Schaefer N, Boughdad S, Baldari S, Gnesin S. Simplified patient-specific renal dosimetry in 177Lu therapy: a proof of concept. Phys Med 2021;92:75-85. [PMID: 34875425 DOI: 10.1016/j.ejmp.2021.11.007] [Reference Citation Analysis]
36 Willowson KP, Eslick E, Ryu H, Poon A, Bernard EJ, Bailey DL. Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE ('Lutate') therapy. EJNMMI Phys 2018;5:33. [PMID: 30569328 DOI: 10.1186/s40658-018-0232-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
37 Vergnaud L, Giraudet AL, Moreau A, Salvadori J, Imperiale A, Baudier T, Badel JN, Sarrut D. Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for [Formula: see text]Lu-DOTATATE therapy. EJNMMI Phys 2022;9:37. [PMID: 35575946 DOI: 10.1186/s40658-022-00462-2] [Reference Citation Analysis]
38 Craig AJ, Rojas B, Wevrett JL, Hamer E, Fenwick A, Gregory R. IPEM topical report: current molecular radiotherapy service provision and guidance on the implications of setting up a dosimetry service. Phys Med Biol 2020;65:245038. [PMID: 33142274 DOI: 10.1088/1361-6560/abc707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Hänscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Absorbed dose estimates from a single measurement one to three days after the administration of 177Lu-DOTATATE/-TOC. Nuklearmedizin 2017;56:219-24. [PMID: 29533417 DOI: 10.3413/Nukmed-0925-17-08] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
40 Sapienza MT, Willegaignon J. Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning. Clinics (Sao Paulo) 2019;74:e835. [PMID: 31365617 DOI: 10.6061/clinics/2019/e835] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
41 Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation Dosimetry in 177Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. J Nucl Med 2020;61:1030-6. [PMID: 31806772 DOI: 10.2967/jnumed.119.233411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
42 Werner RA, Bundschuh RA, Bundschuh L, Lapa C, Yin Y, Javadi MS, Buck AK, Higuchi T, Pienta KJ, Pomper MG, Lodge MA, Gorin MA, Rowe SP. Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. Mol Imaging Biol 2020;22:190-7. [PMID: 31140110 DOI: 10.1007/s11307-019-01375-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
43 Ferdinandus J, Fendler WP, Morigi JJ, Fanti S. Theranostics in oncology: What radiologists want to know. Eur J Radiol 2021;142:109875. [PMID: 34391057 DOI: 10.1016/j.ejrad.2021.109875] [Reference Citation Analysis]
44 Wong RKS, Metser U, Veit-Haibach P. Neuroendocrine Tumors: Imaging Perspective. PET Clin 2021;16:353-64. [PMID: 34053579 DOI: 10.1016/j.cpet.2021.03.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Chicheportiche A, Ben-Haim S, Grozinsky-Glasberg S, Oleinikov K, Meirovitz A, Gross DJ, Godefroy J. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. EJNMMI Phys 2020;7:5. [PMID: 31975156 DOI: 10.1186/s40658-020-0273-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
46 Freedman N, Sandström M, Kuten J, Shtraus N, Ospovat I, Schlocker A, Even-Sapir E. Personalized radiation dosimetry for PRRT-how many scans are really required? EJNMMI Phys 2020;7:26. [PMID: 32394075 DOI: 10.1186/s40658-020-00293-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
47 Lassmann M, Eberlein U. The Relevance of Dosimetry in Precision Medicine. J Nucl Med 2018;59:1494-9. [PMID: 30002109 DOI: 10.2967/jnumed.117.206649] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
48 Kennedy J, Chicheportiche A, Keidar Z. Quantitative SPECT/CT for dosimetry of peptide receptor radionuclide therapy. Semin Nucl Med 2021:S0001-2998(21)00091-X. [PMID: 34911637 DOI: 10.1053/j.semnuclmed.2021.11.004] [Reference Citation Analysis]
49 Huizing DMV, Peters SMB, Versleijen MWJ, Martens E, Verheij M, Sinaasappel M, Stokkel MPM, de Wit-van der Veen BJ. A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy. EJNMMI Phys 2020;7:36. [PMID: 32488632 DOI: 10.1186/s40658-020-00308-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
50 Madsen MT, Menda Y, O'Dorisio TM, O'Dorisio MS. Technical Note: Single time point dose estimate for exponential clearance. Med Phys 2018;45:2318-24. [PMID: 29577338 DOI: 10.1002/mp.12886] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
51 Seo Y, Huh Y, Huang SY, Hernandez-Pampaloni JM, Hawkins RA, Gustafson WC, Vo KT, Matthay KK. Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for 131 I-MIBG therapy of neuroblastoma using 124 I-MIBG PET/CT. Med Phys 2019;46:2477-86. [PMID: 30761545 DOI: 10.1002/mp.13446] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
52 Werner RA, Bengel FM, Derlin T. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors]. Radiologe. 2020;60:413-420. [PMID: 32052116 DOI: 10.1007/s00117-020-00652-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
53 Weich A, Werner RA, Serfling SE, Solnes LB, Pomper MG, Buck AK, Higuchi T, Rowe SP. Rechallenge With Additional Doses of 177Lu-DOTATOC After Failure of Maintenance Therapy With Cold Somatostatin Analogs. Clin Nucl Med 2022. [PMID: 35439179 DOI: 10.1097/RLU.0000000000004239] [Reference Citation Analysis]
54 Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177 Lu-PSMA therapy. Med Phys 2019;46:5861-6. [PMID: 31587333 DOI: 10.1002/mp.13846] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
55 Kelk E, Ruuge P, Rohtla K, Poksi A, Kairemo K. Radiomics Analysis for 177Lu-DOTAGA-(l-y)fk(Sub-KuE) Targeted Radioligand Therapy Dosimetry in Metastatic Prostate Cancer-A Model Based on Clinical Example. Life (Basel) 2021;11:170. [PMID: 33671761 DOI: 10.3390/life11020170] [Reference Citation Analysis]
56 Chiesa C, Strigari L, Pacilio M, Richetta E, Cannatà V, Stasi M, Marzola MC, Schillaci O, Bagni O, Maccauro M. Dosimetric optimization of nuclear medicine therapy based on the Council Directive 2013/59/EURATOM and the Italian law N. 101/2020. Position paper and recommendations by the Italian National Associations of Medical Physics (AIFM) and Nuclear Medicine (AIMN). Phys Med 2021;89:317-26. [PMID: 34583307 DOI: 10.1016/j.ejmp.2021.07.001] [Reference Citation Analysis]
57 Werner RA, Weich A, Kircher M, Solnes LB, Javadi MS, Higuchi T, Buck AK, Pomper MG, Rowe SP, Lapa C. The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go? Theranostics 2018;8:6088-100. [PMID: 30613284 DOI: 10.7150/thno.30357] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
58 Turner JH. Recent advances in theranostics and challenges for the future. Br J Radiol 2018;91:20170893. [PMID: 29565650 DOI: 10.1259/bjr.20170893] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
59 Current K, Meyer C, Magyar CE, Mona CE, Almajano J, Slavik R, Stuparu AD, Cheng C, Dawson DW, Radu CG, Czernin J, Lueckerath K. Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity. Clin Cancer Res 2020;26:2946-55. [PMID: 31932492 DOI: 10.1158/1078-0432.CCR-19-1485] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 13.5] [Reference Citation Analysis]
60 Finocchiaro D, Gear JI, Fioroni F, Flux GD, Murray I, Castellani G, Versari A, Iori M, Grassi E. Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy. EJNMMI Phys 2020;7:63. [PMID: 33044651 DOI: 10.1186/s40658-020-00328-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
61 Della Gala G, Bardiès M, Tipping J, Strigari L. Overview of commercial treatment planning systems for targeted radionuclide therapy. Phys Med 2021;92:52-61. [PMID: 34864422 DOI: 10.1016/j.ejmp.2021.11.001] [Reference Citation Analysis]
62 Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging 2019;46:728-42. [PMID: 30506283 DOI: 10.1007/s00259-018-4209-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
63 Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol 2021;102-103:1-11. [PMID: 34242948 DOI: 10.1016/j.nucmedbio.2021.06.006] [Reference Citation Analysis]
64 Park EA, Graves SA, Menda Y. The Impact of Radiopharmaceutical Therapy on Renal Function. Seminars in Nuclear Medicine 2022. [DOI: 10.1053/j.semnuclmed.2022.02.004] [Reference Citation Analysis]